References

1. George JN, Nester CM: Syndromes of thrombotic microangiopathy. N Engl J Med
2014; 371:1847-1848.
2. Chapman K, Seldon M, Richards R. Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13. Semin Thromb Hemost 2012; 38:47-54.
3. George JN, Sandler SA, Stankiewicz J. Management of thrombotic thrombocytopenic purpura without plasma exchange: the Jehovah’s Witness experience. Blood Adv 2017; 1:2161-2165.
4. Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012; 158:323-335.
5. Froissart A, Buffet M, Veyradier A, et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med 2012; 40:104-111.
6. Dimopoulou D, Dimosiari A, Mandala E, et al. Autoimmune Thrombotic Thrombocytopenic Purpura: Two Rare Cases Associated with Juvenile Idiopathic Arthritis and Multiple Sclerosis. Front Med (Lausanne) 2017; 4:89.
7. Zhang C, Chen XH, Zhang X. Quick development and sudden death: Evans syndrome followed by thrombotic thrombocytopenic purpura. Am J Emerg Med 2014; 32:1156. e1153-1154.
8. Page EE, Kremer Hovinga JA, Terrell DR, et al. Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Adv 2017; 1:590-600.
9. Howard MA, Williams LA, Terrell DR, et al. Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion 2006; 46:154-156.
10. Oshima T, Ikutomi M, Shinohara H, et al. Acute Myocardial Infarction Caused by Thrombotic Microangiopathy Complicated with Myelodysplastic Syndrome. Int Heart J 2016; 57:634-636.
11. Dewachter P, Mouton-Faivre C, Mertes PM. Preventing complications of central venous catheterization. N Engl J Med 2003; 348:2684-2686; author reply 2684-2686.
12. Rottenstreich A, Kalish Y, Tvito A, et al. Acquired thrombotic thrombocytopenic purpura in pregnancy: The role of placental and breast-milk mediated transfer of ADAMTS13-autoantibodies. Thromb Res 2017; 156:80-81.
13. Nakao H, Ishiguro A, Ikoma N, et al. Acquired idiopathic thrombotic thrombocytopenic purpura successfully treated with intravenous immunoglobulin and glucocorticoid: A case report. Medicine (Baltimore) 2017; 96: e6547.
14. Rituximab prevents long-term relapses in TTP. Blood 2018; 132:2210.
15. Thumma S, Idrees S, Phuyal P, et al.When the Standard Treatment Fails: Rituximab Therapy for Refractory TTP. Am J Ther 2018.
16. Peyvandi F, Scully M, Kremer Hovinga JA, et al. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med 2016; 374:511-522.